EXHIBIT 10.30.4
Published on March 31, 2025
Exhibit 10.30.4
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS
AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***]
AMENDMENT NO. 4 TO EXCLUSIVE LICENSE AGREEMENT WITH KNOW-HOW
This Amendment No. 4 to Exclusive License Agreement with Know-How (“Amendment”)
is made effective as of April 15, 2024, by and among the Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), the University of Florida Research Foundation, Incorporated, a nonstock, nonprofit Florida corporation
(“UFRF”; together with Penn, the “Licensors”) and Opus Genetics Inc. (“Licensee”).
RECITALS:
WHEREAS, the Licensors and Licensee entered into an Exclusive License Agreement with Know-How, dated as of April 10, 2019, as amended by
Amendment No. 1 on May 1, 2020, Amendment No. 2 dated July 1, 2022 and Assignment Consent Agreement and Third Amendment dated December 23, 2022 (the “License Agreement”) pursuant
to which the Licensors granted Licensee exclusive rights to certain patent rights and know-how and non-exclusive rights to certain know-how, in each case to develop, manufacture and commercialize certain gene therapy technologies in the field of
treating diseases associated with mutations in the BEST1 gene; and
WHEREAS, the parties now desire to modify the Diligence Events and wish to amend the License Agreement to reflect these changes. Capitalized
terms used but not defined herein shall have the meanings ascribed to them in the License Agreement.
NOW THEREFORE, in consideration of the premises and mutual covenants contained herein the parties hereto agree as follows:
|
|
1. |
Appendix F — Milestones. Appendix F-1 is hereby
deleted in its entirety and replaced with the following:
|
Diligence Events for Wildtype Only Products
|
Diligence Event
|
Achievement Date
|
|
[***]
|
[***]
|
|
[***]
|
[***]
|
|
[***]
|
[***]
|
|
|
2. |
Except as expressly set forth in this Amendment No. 4, the License Agreement remains in full force and effect in accordance with its terms.
|
|
|
3. |
This Amendment No. 4 may be executed in counterparts, each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. A portable
document format (PDF) or electronic copy of this Amendment No. 4, including the signature pages, will be deemed an original. The parties hereby agree that this Amendment No. 4 may be executed with electronic signatures and shall be valid and
binding on the parties to the extent electronically signed.
|
[Signatures follow]
This Amendment No. 4 to Exclusive License Agreement with Know-How is entered into by the parties by their duly authorized signatories.
|
Licensors:
|
|
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
|
|
By: /s/ Benjamin Dibling, Ph.D.
|
|
Name: Benjamin Dibling, Ph.D.
|
|
Title: Associate Vice Provost for Research and Managing Director, Penn Center for Innovation
|
|
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
|
|
By: /s/ Jim O’Connell
|
|
Name: Jim O’Connell
|
|
Title: Director, UF Innovate | Tech Licensing
|
|
Licensee:
|
|
OPUS GENETICS INC.
|
|
By: /s/ Ben Yerxa
|
|
Name: Ben Yerxa
|
|
Title: Chief Executive Officer
|